Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
– Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million
– Q3 2022 North American Revenue Growth of 19%
– TH1902 Phase 1 basket trial proceeding as planned
Related news for (THTX)
- MoBot alert highlights: NASDAQ: CMND, NASDAQ: LRHC, NASDAQ: THTX, NASDAQ: WINT, NASDAQ: EMPG (07/03/25 08:00 AM)
- Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
- 24/7 Market News Snapshot 03 July, 2025 – Theratechnologies Inc. Common (NASDAQ:THTX)
- Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
- Theratechnologies Provides Update on Sale Process